Literature DB >> 24743150

Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.

Dallas B Flies, Xue Han, Tomoe Higuchi, Linghua Zheng, Jingwei Sun, Jessica Jane Ye, Lieping Chen.   

Abstract

T cell activation is regulated by the interactions of surface receptors with stimulatory and inhibitory ligands. Programmed death-1 homolog (PD-1H, also called VISTA) is a member of the CD28 family of proteins and has been shown to act as a coinhibitory ligand on APCs that suppress T cell responses. Here, we determined that PD-1H functions as a coinhibitory receptor for CD4⁺ T cells. CD4⁺ T cells in mice lacking PD-1H exhibited a dramatically increased response to antigen stimulation. Furthermore, delivery of a PD-1H-specific agonist mAb directly inhibited CD4⁺ T cell activation both in vitro and in vivo, validating a coinhibitory function of PD-1H. In a murine model of acute hepatitis, administration of a PD-1H agonist mAb suppressed CD4⁺ T cell-mediated acute inflammation. PD-1H-deficient animals were highly resistant to tumor induction in a murine brain glioma model, and depletion of CD4⁺ T cells, but not CD8⁺ T cells, promoted tumor formation. Together, our findings suggest that PD-1H has potential as a target of immune modulation in the treatment of human inflammation and malignancies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24743150      PMCID: PMC4001557          DOI: 10.1172/JCI74589

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models.

Authors:  Dallas B Flies; Shengdian Wang; Haiying Xu; Lieping Chen
Journal:  J Immunol       Date:  2011-07-18       Impact factor: 5.422

Review 3.  Immunologically augmented cancer treatment using modern radiotherapy.

Authors:  Marco Durante; Norman Reppingen; Kathryn D Held
Journal:  Trends Mol Med       Date:  2013-07-04       Impact factor: 11.951

4.  A mouse knockout library for secreted and transmembrane proteins.

Authors:  Tracy Tang; Li Li; Jerry Tang; Yun Li; Wei Yu Lin; Flavius Martin; Deanna Grant; Mark Solloway; Leon Parker; Weilan Ye; William Forrest; Nico Ghilardi; Tamas Oravecz; Kenneth A Platt; Dennis S Rice; Gwenn M Hansen; Alejandro Abuin; Derek E Eberhart; Paul Godowski; Kathleen H Holt; Andrew Peterson; Brian P Zambrowicz; Frederic J de Sauvage
Journal:  Nat Biotechnol       Date:  2010-06-20       Impact factor: 54.908

5.  Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain.

Authors:  Michael J Moravan; John A Olschowka; Jacqueline P Williams; M Kerry O'Banion
Journal:  Radiat Res       Date:  2011-07-25       Impact factor: 2.841

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

Review 8.  CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Authors:  Patrick A Ott; F Stephen Hodi; Caroline Robert
Journal:  Clin Cancer Res       Date:  2013-10-01       Impact factor: 12.531

9.  Cancer control related to stimulation of immunity by low-dose radiation.

Authors:  Shu-Zheng Liu
Journal:  Dose Response       Date:  2006-08-28       Impact factor: 2.658

10.  Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.

Authors:  Lukas Baitsch; Amandine Legat; Leticia Barba; Silvia A Fuertes Marraco; Jean-Paul Rivals; Petra Baumgaertner; Céline Christiansen-Jucht; Hanifa Bouzourene; Donata Rimoldi; Hanspeter Pircher; Nathalie Rufer; Maurice Matter; Olivier Michielin; Daniel E Speiser
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

View more
  99 in total

1.  Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.

Authors:  Lei Zhang; John S Yu
Journal:  J Neurooncol       Date:  2019-05-31       Impact factor: 4.130

Review 2.  Targeting immune checkpoints in melanoma: an update.

Authors:  Rodrigo R Munhoz; Alejandro Falcón González; Vanessa A Reed; Michael A Postow
Journal:  Melanoma Manag       Date:  2015-11-24

3.  A VISTA on PD-1H.

Authors:  Yang Liu
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

4.  Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Authors:  Franz Villarroel-Espindola; Xiaoqing Yu; Ila Datar; Nikita Mani; Miguel Sanmamed; Vamsidhar Velcheti; Konstantinos Syrigos; Maria Toki; Hongyu Zhao; Lieping Chen; Roy S Herbst; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2017-12-04       Impact factor: 12.531

5.  VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.

Authors:  Sabrina Ceeraz; Susan K Eszterhas; Petra A Sergent; David A Armstrong; Alix Ashare; Thomas Broughton; Li Wang; Dov Pechenick; Christopher M Burns; Randolph J Noelle; Matthew P Vincenti; Roy A Fava
Journal:  Arthritis Res Ther       Date:  2017-12-08       Impact factor: 5.156

Review 6.  Emerging roles of p53 and other tumour-suppressor genes in immune regulation.

Authors:  César Muñoz-Fontela; Anna Mandinova; Stuart A Aaronson; Sam W Lee
Journal:  Nat Rev Immunol       Date:  2016-09-26       Impact factor: 53.106

7.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

Review 8.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation.

Authors:  Wenwen Xu; TạMinh Hiếu; Subramaniam Malarkannan; Li Wang
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.